Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Behind the NICE Alzheimer’s reversal

Friday, November 5th, 2010

You may be wondering what convinced the National Institute for Health and Clinical Excellence, U.K.’s controversial drug-cost watchdog, to reverse its restrictions on four top Alzheimer’s disease medicines last month, opening up potential access to hundreds of thousands of sufferers previously denied coverage. No, it doesn’t appear the result of a ...

Posted in CRO, Uncategorized | No Comments »

Mental illness R&D reaches record level

Tuesday, July 20th, 2010

Offering further proof of the lucrative appeal of mental health drugs despite the continuing minefield for researchers, there are a record 313 new drugs in development to treat conditions ranging from Alzheimer’s disease and depression to schizophrenia and addictive disorders, according to a new report by the Pharmaceutical Researchers and ...

Posted in Uncategorized, clinical trials | 2 Comments »

Clumps key in Huntington’s disease breakthrough

Friday, June 5th, 2009

Scientists have figured out the cause of brain damage and death in Huntington’s disease patients that may lead to treatments to stop the disease. There is currently only one treatment that eases the symptoms of Huntington’s, Xenazine, marketed and developed by H. Lundbeck. Although there are a handful of drugs ...

Posted in clinical trials, filed for approval | No Comments »

   
about us | advertise | contact us | home
terms of use | privacy | copyright | site map 		©2012 UBM Canon